Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura

Sohag University

Status: Enrolling

Conditions: ITP - Immune Thrombocytopenia

Treatments: Drug: Eltrombopag

Study type: Interventional

Funder types: Other

Identifiers

NCT07093606

Soh-Med--25-7-4MS

Details and patient eligibility

About

this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.

Enrollment: 100 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria Adult patients (≥18 years) diagnosed with primary ITP. Receiving eltrombopag as part of their treatment. Baseline liver function tests (LFTs) within normal limits. Patients with diabetes Patients without diabetes Patients with fatty liver Patients without fatty liver

Exclusion Criteria:

Pre-existing liver disease (e.g., hepatitis, cirrhosis, NAFLD). Concurrent use of hepatotoxic drugs. Patients lost to follow-up.

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

this group will receive Eltrombopag tabelts

Experimental group

Description:

ITP patients in this group receive Eltrombopag then follow up by liver functions test to evulate occurance of liver disorders .

Treatment:

Drug: Eltrombopag